HR 1262 · introduced · significant
Mikaela Naylon Give Kids a Chance Act
- healthcare
What this bill does
- The bill expands FDA authority to oversee research on rare pediatric diseases and enforce compliance with pediatric study requirements.
- Pharmaceutical companies developing drugs for rare pediatric diseases and childhood cancers are affected by new compliance rules.
- The bill reauthorizes pediatric research funding through 2027 and extends priority review voucher authority through September 2029.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How might expanded FDA oversight of rare pediatric disease research change which treatments get developed and reach children fastest?
- 02
What trade-offs exist between stricter pharmaceutical compliance requirements and companies' willingness to invest in drugs for rare childhood diseases?
- 03
Why does the bill extend priority review vouchers through 2029, and how could that incentive affect pharmaceutical research priorities?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · R-TX-10
Michael T. McCaul
Citizen cosponsors
0
In Congress
313/ 435
House Reps cosponsoring
Introduced 2025-12-02
Joining the bill
Lori Trahan
D-MA-3 · original
Dan Crenshaw
R-TX-2 · original
Mike Kelly
R-PA-16 · original
Kim Schrier
D-WA-8 · original
Randy K. Weber, Sr.
R-TX-14 · original
Kathy Castor
D-FL-14 · original
Diana Harshbarger
R-TN-1 · original
Gus M. Bilirakis
R-FL-12 · original
Debbie Dingell
D-MI-6 · original
Doris O. Matsui
D-CA-7 · original
Carlos A. Gimenez
R-FL-28
Clay Higgins
R-LA-3
+ 301 more
Legislative timeline
2025-12-02 · senate · IntroReferral
Received in the Senate.
2025-12-01 · house · Floor
Motion to reconsider laid on the table Agreed to without objection.
2025-12-01 · house · Floor
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4929-4932)
2025-12-01 · Floor
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4929-4932)
2025-12-01 · house · Floor
DEBATE - The House proceeded with forty minutes of debate on H.R. 1262.
2025-12-01 · house · Floor
Considered under suspension of the rules. (consideration: CR H4929-4935)
2025-12-01 · house · Floor
Mr. Carter (GA) moved to suspend the rules and pass the bill, as amended.
2025-10-31 · house · Calendars
Placed on the Union Calendar, Calendar No. 304.
2025-10-31 · house · Committee
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-352.
2025-10-31 · Committee
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-352.
2025-09-17 · house · Committee
Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 47 - 0.
2025-09-17 · house · Committee
Committee Consideration and Mark-up Session Held
2025-02-12 · house · IntroReferral
Referred to the House Committee on Energy and Commerce.
2025-02-12 · IntroReferral
Introduced in House
2025-02-12 · IntroReferral
Introduced in House
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.